Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age

Vaccines against Seasonal and Pandemic Influenza and the Implications of Changes in Substrates for Virus Production

(2010) Philip D. Minor   CLINICAL INFECTIOUS DISEASES

Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy Adults

(2010) Sharon Frey et al.   CLINICAL INFECTIOUS DISEASES

Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United States

(2009) N. E. Basta et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines

(2009) P Noel Barrett et al.   Expert Review of Vaccines

Influenza Vaccine Manufacture: Keeping Up with Change

(2009) Kathleen M. Neuzil et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture

(2009) Agnieszka Szymczakiewicz‐Multanowska et al.   JOURNAL OF INFECTIOUS DISEASES

Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity

(2009) Keith S. Reisinger et al.   JOURNAL OF INFECTIOUS DISEASES

A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine

(2009) Arvydas Ambrozaitis et al.   VACCINE

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial

(2008) N. Groth et al.   VACCINE